AC
LENZ

Aldebaran Capital’s LENZ Therapeutics LENZ Stock Holding History

Aldebaran Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,571
Closed -$322K – 33
2023
Q3 		$322K Hold
18,571
– – 0.33% 28
2023
Q2 		$338K Hold
18,571
– – 0.35% 26
2023
Q1 		$319K Buy
+18,571
New +$300K 0.33% 28

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aldebaran Capital's LENZ Position: Q4 2023 in Review

Aldebaran Capital sold out of LENZ Therapeutics (LENZ) in Q4 2023, closing a stake of 18,571 shares — an estimated $322K sold.

Aldebaran Capital first reported a position in LENZ in Q1 2023 and held it in 3 quarters. The position peaked at $338K in Q2 2023. 63 funds tracked by Wall St. Rank hold LENZ as of Q4 2023.

  • Aldebaran Capital reported no remaining LENZ Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Aldebaran Capital sold 18,571 LENZ Therapeutics shares in Q4 2023, an estimated $322K.
  • Aldebaran Capital first reported a position in LENZ Therapeutics in Q1 2023 and held it in 3 quarters.
  • Aldebaran Capital's LENZ Therapeutics position peaked at $338K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2023.

Based on Aldebaran Capital's 13F filing for Q4 2023, filed 13 Feb 2024.